Good MorningA new trading year has begun, which should be good for investors. Easing monetary, regulatory, and tax headwinds are expected to accelerate economic activity and sustain upward momentum in stock prices.
The S&P 500 index ended 2024 on a downbeat, closing lower on the year's final day, but the uptrend is intact and expected to hit new highs early in the year. A move to new highs is also significant because of the technical signals, which indicate another 1,300-point gain by the end of the year.
This week and next week are critical for market direction in 2025. The labor data is due this week, and earnings from the big banks next. The labor data should align with trends, including steady job creation, low unemployment, and rising wages and earnings from the banks should be robust. Top financial firms, including banks like JPMorgan Chase, are expected to grow earnings by high-double digits, averaging nearly 40% for the group. Featured: Trump goes "all-in" on Grand Canyon energy breakthrough (Ad) 
|
Consumer Discretionary | |
Tesla Inc (NASDAQ: TSLA) shares are rounding out a phenomenal year, delivering gains as much as 250% off the back of decent performance and a favorable macro environment. For example, much of this year’s rally has been fueled by strong investor sentiment following geopolitical developments... Read the Full Story |
|
From Our Partners | | Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies.
Dr. Mark Skousen, who met Musk in person and called the SpaceX listing months early, says he has identified all three targets in what he calls Elon's $2.1 Trillion Hit List.
See the three companies before the rumors become headlines. | | Get the details on all three companies now |
|
Markets | |
The travel and leisure sectors are undergoing a transformation driven by the rising popularity of Bleisure travel—a blend of "business" and "leisure."
Bleisure travel represents a fundamental shift in how people approach travel. It reflects a broader societal trend where the boundaries... Read the Full Story |
|
Energy | |
The concept of market relativity is more alive than ever in today’s economy, as gone are the days of individualistic price action in different asset classes and even stocks. With the advances in data delivery and technology, traders across the financial sector have found ways to connect the ... Read the Full Story |
|
From Our Partners | | More than 25 candidates were screened for share price between $1 and $5, market cap above $100 million, daily volume over 500,000 shares, and over $10 million in trailing revenue.
Only five stocks cleared every filter, spanning five different sectors. Two are profitable today, and one pays a substantial dividend.
The report also flags what could go wrong with each pick, including dilution and convertible debt. | | See the five stocks that survived this strict revenue screen |
|
Technology | |
Global enterprise software giant SAP SE (NYSE: SAP) has been scratching at all-time highs as its business gets lifted by artificial intelligence (AI) tailwinds. SAP is an acronym for Systems, Applications, and Products in Data Processing. The company provides cloud-based business software through ... Read the Full Story |
|
Markets | |
Artificial intelligence stocks are expected to continue showing strong growth in 2025. Much of the attention focuses on the opportunity that comes from the buildout of data centers. But a practical area where AI has been making significant inroads is healthcare.
For some investors, the fir... Read the Full Story |
|
From Our Partners | | Barrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourmile, Goldrush, and Cortez Hills, a region that could hold as much as 60 million ounces of gold.
Bordering Fourmile and less than a mile from Goldrush sits a little-known explorer now moving from historical data toward active exploration, setting targets and preparing for a maiden drilling program.
With gold trading near record highs, this could be a pivotal stage for an overlooked name in the district. | | See why this overlooked gold explorer could be entering its most important stage |
|
Materials | |
Share buybacks are an important way that corporate management teams look to return value to their shareholders. Buying back stock decreases the number of outstanding shares a company has in the market. Because there are fewer shares, the company’s earnings per share rise, all else held equal... Read the Full Story |
|
Markets | |
It has been a strong year for stocks, and the best may be yet to come.
With only one trading day left in 2024, the S&P 500 Index is up approximately 23%. However, as investors look back on the year, they’ll see a textbook example of why the stock market is a poor proxy for the economy,... Read the Full Story |
|
Industrials | |
Joby Aviation Inc. (NYSE: JOBY), a pioneering company in electric vertical takeoff and landing (eVTOL) aircraft, has experienced a stellar end to the year. The stock is up 66% this quarter, bringing its year-to-date gains to 26% as of Monday’s close. As capital flows into high-growth and hig... Read the Full Story |
|
Industrials | |
The Boeing Co. (NYSE: BA) is coming off a rocky 2024 as it got plied with regulatory issues, terrible public relations, regulatory scrutiny from the FAA and NTSB and a worker’s strike that cost the company billions of dollars. The aerospace sector leader started 2024 on a high note, trading ... Read the Full Story |
|
Consumer Discretionary | |
When it comes to used cars in the United States, CarMax Inc. (NYSE: KMX) stands out as the largest used car dealership. The auto/tires/trucks sector giant operates more than 245 physical dealerships in the country, and it popularized the concept of a “no-haggle” pricing policy for buyi... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada. | | View Today's Stock Pick |
|
